Skip to content

Study · Randomized controlled trial · n = 16 · 2016

1 result

Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial.

Quintana DS, Westlye LT, Alnæs D, Rustan ØG, Kaufmann T, Smerud KT, Mahmoud RA, Djupesland PG, Andreassen OA

Psychoneuroendocrinology22 Apr 2016Cited by 87 (Europe PMC)

PMID27107209 (opens in a new tab)DOI10.1016/j.psyneuen.2016.04.010 (opens in a new tab)PepBankPUB-27107209
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men, a low dose of 8IU intranasal oxytocin reduced right amygdala activation during processing of angry and happy faces compared with placebo.

    In plain wordsIn healthy men, a low oxytocin nasal dose lowered amygdala activity to emotional faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseRight amygdala activation during angry and happy face processing
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    8IU · intranasal · single doseAs given in this study (human).

    Measurements

    Dose
    8 IU
    low dose intranasal

    Source sentences

    Summary
    We observed a treatment effect on right amygdala activation during the processing of angry and happy face stimuli, with pairwise comparisons revealing reduced activation after the 8IU low dose intranasal treatment compared to placebo.
    1 context sentence
    Summary · context
    We adopted a randomized, double-blind, double-dummy, crossover design, with 16 healthy male adults administering a single-dose of these four treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06945926

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Zhejiang Universityn = 2271 Jun 2025 to 2 Jun 2026

Cervical Spinal Stenosis · Thoracic Spinal Stenosis · Lumbar Spinal Stenosis · Rotator Cuff Injury · Femoral Head Necrosis · Spinal Trauma · Knee Joint Injury

Trial pageClinicalTrials.govUpdated 20 Aug 2026
CompletedPhase 1NCT01983514

Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults

OptiNose ASn = 19Oct 2013 to Feb 2014

Healthy Male Adults

Trial pageClinicalTrials.govUpdated 23 Apr 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.